Macular Edema - Pipeline Review, H1 2016

This report is available at upto 25% Discount. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.

Global Markets Direct’s, ‘Macular Edema - Pipeline Review, H1 2016’, provides an overview of the Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape of Macular Edema
• The report reviews pipeline therapeutics for Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Macular Edema therapeutics and enlists all their major and minor projects
• The report assesses Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Macular Edema

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Macular Edema
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

This report is available at upto 25% Discount. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Macular Edema Overview 8
Therapeutics Development 9
Pipeline Products for Macular Edema - Overview 9
Macular Edema - Therapeutics under Development by Companies 10
Macular Edema - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Macular Edema - Products under Development by Companies 16
Macular Edema - Companies Involved in Therapeutics Development 17
ActiveSite Pharmaceuticals, Inc. 17
Ampio Pharmaceuticals, Inc. 18
Clearside BioMedical, Inc. 19
Clonz Biotech Private Limited 20
Coherus BioSciences, Inc. 21
EyeGate Pharmaceuticals, Inc. 22
Mabion SA 23
Pfizer Inc. 24
Precision Ocular Ltd 25
Promedior, Inc. 26
Taiwan Liposome Company, Ltd. 27
Valeant Pharmaceuticals International, Inc. 28
Xbrane Biopharma AB 29
Macular Edema - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(aflibercept + triamcinolone acetonide) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ACX-107 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ASPPDC-020 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
BLO-021 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
celecoxib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
danazol - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
dexamethasone acetate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
dexamethasone sodium phosphate SR - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Drugs for Retinal Diseases - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
PRM-167 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ranibizumab biosimilar - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ranibizumab biosimilar - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ranibizumab biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ranibizumab biosimilar - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
triamcinolone acetonide - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Macular Edema - Recent Pipeline Updates 59
Macular Edema - Dormant Projects 67
Macular Edema - Discontinued Products 68
Macular Edema - Product Development Milestones 69
Featured News & Press Releases 69
Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion 69
Jan 05, 2016: Clearside Biomedical Announces Positive Topline Data from Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis 69
Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration 70
Dec 07, 2015: Clearside Biomedical, Inc. Enrolls First Patient in Phase 3 Clinical Trial of CLS-TA Using Suprachoroidal Drug Administration 71
Oct 12, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA Using Suprachoroidal Space Drug Administration 71
Jun 16, 2015: Clearside Biomedical Announces Favorable End-of-Phase 2 Review with the FDA 72
Mar 02, 2015: Clearside Biomedical Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion 72
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables

Number of Products under Development for Macular Edema, H1 2016 9
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Comparative Analysis by Unknown Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H1 2016 17
Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 18
Macular Edema - Pipeline by Clearside BioMedical, Inc., H1 2016 19
Macular Edema - Pipeline by Clonz Biotech Private Limited, H1 2016 20
Macular Edema - Pipeline by Coherus BioSciences, Inc., H1 2016 21
Macular Edema - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2016 22
Macular Edema - Pipeline by Mabion SA, H1 2016 23
Macular Edema - Pipeline by Pfizer Inc., H1 2016 24
Macular Edema - Pipeline by Precision Ocular Ltd, H1 2016 25
Macular Edema - Pipeline by Promedior, Inc., H1 2016 26
Macular Edema - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 27
Macular Edema - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 28
Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2016 29
Assessment by Monotherapy Products, H1 2016 30
Assessment by Combination Products, H1 2016 31
Number of Products by Stage and Target, H1 2016 33
Number of Products by Stage and Mechanism of Action, H1 2016 35
Number of Products by Stage and Route of Administration, H1 2016 37
Number of Products by Stage and Molecule Type, H1 2016 39
Macular Edema Therapeutics - Recent Pipeline Updates, H1 2016 59
Macular Edema - Dormant Projects, H1 2016 67
Macular Edema - Discontinued Products, H1 2016 68

List of Figures

Number of Products under Development for Macular Edema, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 30
Number of Products by Targets, H1 2016 32
Number of Products by Stage and Targets, H1 2016 32
Number of Products by Mechanism of Actions, H1 2016 34
Number of Products by Stage and Mechanism of Actions, H1 2016 34
Number of Products by Routes of Administration, H1 2016 36
Number of Products by Stage and Routes of Administration, H1 2016 36
Number of Products by Molecule Types, H1 2016 38
Number of Products by Stage and Molecule Types, H1 2016 38